Butchertown Clinical Trials Announces 25th FDA Approval
Tenpoint Therapeutics Gains US FDA Approval of YuvezziTM for the Treatment of Presbyopia
January 29, 2026
Butchertown Clinical Trials, an independent ophthalmic clinical trials site in Louisville, Kentucky, reaches its 25th US FDA Approval milestone for its work on YUVEZZI.
According to the Tenpoint press release, YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is the only dual-agent presbyopia-correcting eye drop intentionally designed to deliver durability, tolerability, and safety. YUVEZZI becomes effective at about 30 minutes after instillation and works for up to 10 hours with one drop daily.
Principal Investigator, John C. Meyer, MD, stated “From my work in helping develop this new medication through the clinical trials process, I became quite impressed that this is a good option for persons looking to reduce or eliminate their need for reading glasses, on a temporary basis, without surgery.” Dr. Meyer continued by stating scientific advances to help those who often say they “need longer arms” now includes not only glasses and contact lenses, but laser and implant surgery, as well as eyedrops.
A decade ago, when deciding to spin off our clinical trials department into a standalone entity, later called Butchertown Clinical Trials, our team did not anticipate reaching the milestone of 25 US FDA approvals, said CEO and Co-Founder, Mark Prussian. He continued, “Our work on almost 500 clinical trials has led to new treatments for glaucoma, dry eye disease, presbyopia, eye pain, and more, as well as advancements in artificial intelligence, “ Prussian continued.
As an ophthalmic clinical trials site, Butchertown Clinical Trials typically enters into contracts with biotechnology firms or pharmaceutical companies to follow a scientific protocol to test proposed eye medications or new formulations of existing eye medications against either a placebo or an already approved medication. Butchertown Clinical Trials then reports the trial data to the contracting firm, which analyzes it and presents it to the FDA for potential approval of new treatments.
Butchertown Clinical Trials conducted the trials for YUVEZZI with the former sponsor, Visus Therapeutics, which was acquired by Tenpoint Therapeutics in 2024.
Butchertown Clinical Trials, an affiliate of The Eye Care Institute, is the largest ophthalmic clinical trial site in the US, Prussian stated.
# # #
